Cell mediated reactions create TGF-β delivery limitations in engineered cartilage
Source abstract
Abstract
During native cartilage development, endogenous TGF-β activity is tightly regulated by cell-mediated chemical reactions in the extracellular milieu (e.g., matrix and receptor binding), providing spatiotemporal control in a manner that is localized and short acting. These regulatory paradigms appear to be at odds with TGF-β delivery needs in tissue engineering (TE) where administered TGF-β is required to transport long distances or reside in tissues for extended durations. In this study, we perform a novel examination of the influence of cell-mediated reactions on the spatiotemporal distribution of administered TGF-β in cartilage TE applications. Reaction rates of TGF-β binding to cell-deposited ECM and TGF-β internalization by cell receptors are experimentally characterized in bovine chondrocyte-seeded tissue constructs. TGF-β binding to the construct ECM exhibits non-linear Brunauer-Emmett-Teller (BET) adsorption behavior, indicating that as many as seven TGF-β molecules can aggregate at a binding site. Cell-mediated TGF-β internalization rates exhibit a biphasic trend, following a Michaelis-Menten relation (Vmax = 2.4 molecules cell-1 s-1, Km = 1.7 ng mL-1) at low ligand doses (≤130 ng/mL), but exhibit an unanticipated non-saturating power trend at higher doses (≥130 ng/mL). Computational models are developed to illustrate the influence of these reactions on TGF-β spatiotemporal delivery profiles for conventional TGF-β administration platforms. For TGF-β delivery via supplementation in culture medium, these reactions give rise to pronounced steady state TGF-β spatial gradients; TGF-β concentration decays by ∼90 % at a depth of only 500 μm from the media-exposed surface. For TGF-β delivery via heparin-conjugated affinity scaffolds, cell mediated internalization reactions significantly reduce the TGF-β scaffold retention time (160-360-fold reduction) relative to acellular heparin scaffolds. This work establishes the significant limitations that cell-mediated chemical reactions engender for TGF-β delivery and highlights the need for novel delivery platforms that account for these reactions to achieve optimal TGF-β exposure profiles. STATEMENT OF SIGNIFICANCE: During native cartilage development, endogenous TGF-β activity is tightly regulated by cell-mediated chemical reactions in the extracellular milieu (e.g., matrix and receptor binding), providing spatiotemporal control in a manner that is localized and short acting. However, the effect of these reactions on the delivery of exogenous TGF-β to engineered cartilage tissues remains not well understood. In this study, we demonstrate that cell-mediated reactions significantly restrict the delivery of TGF-β to cells in engineered cartilage tissue constructs. For delivery via media supplementation, reactions significantly limit TGF-β penetration into constructs. For delivery via scaffold loading, reactions significantly limit TGF-β residence time in constructs. Overall, these results illustrate the impact of cell-mediated chemical reactions on TGF-β delivery profiles and support the importance of accounting for these reactions when designing TGF-β delivery platforms for promoting cartilage regeneration.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Osteoarthritis Treatment and Mechanisms · Cell Adhesion Molecules Research · TGF-β signaling in diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. High seeding density of human chondrocytes in agarose produces tissue-engineered cartilage approaching native mechanical and biochemical properties10.1016/j.jbiomech.2016.04.039 ↗
2. Transient exposure to transforming growth factor beta 3 under serum-free conditions enhances the biomechanical and biochemical maturation of tissue-engineered cartilage10.1089/ten.tea.2007.0222 ↗
3. Tissue engineering of functional articular cartilage: the current status10.1007/s00441-011-1243-1 ↗
4. The beneficial effect of delayed compressive loading on tissue-engineered cartilage constructs cultured with TGF-β310.1016/j.joca.2007.03.008 ↗
5. Self-assembling peptide hydrogel fosters chondrocyte extracellular matrix production and cell division: Implications for cartilage tissue repair10.1073/pnas.142309999 ↗
6. TGF-beta signaling in cartilage homeostasis and osteoarthritis
7. Transforming growth factor-beta stimulates synthesis of proteoglycan aggregates in calf articular cartilage organ cultures10.1016/0003-9861(91)90013-9 ↗
8. Transient exposure to transforming growth factor beta 3 improves the mechanical properties of mesenchymal stem cell-laden cartilage constructs in a density-dependent manner10.1089/ten.tea.2009.0198 ↗
9. Transforming growth factor beta-releasing scaffolds for cartilage tissue engineering10.1089/ten.teb.2013.0271 ↗
10. Self-assembling peptide hydrogels modulate in vitro chondrogenesis of bovine bone marrow stromal cells10.1089/ten.tea.2009.0158 ↗
11. Heparin-bound transforming growth factor-β3 enhances neocartilage formation by rabbit mesenchymal stem cells10.1097/TP.0b013e3181639b3a ↗
12. Physiologic doses of transforming growth factor-beta improve the composition of engineered articular cartilage
13. Cartilage cell clusters10.1002/art.27528 ↗
14. Differential role of transforming growth factor-beta in an osteoarthritic or a healthy joint10.11005/jbm.2018.25.2.65 ↗
15. Nutrient channels and stirring enhanced the composition and stiffness of large cartilage constructs10.1016/j.jbiomech.2014.10.017 ↗
16. Constrained cage culture improves engineered cartilage functional properties by enhancing collagen network stability10.1089/ten.tea.2016.0467 ↗
17. Interaction of chondrocytes, extracellular matrix and growth factors: Relevance for articular cartilage tissue engineering10.1053/joca.2002.0806 ↗
18. Transforming growth factor-beta 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint
19. Latent TGF-β binding proteins: extracellular matrix association and roles in TGF-β activation10.1080/10408360490460933 ↗
20. Biological significance and mechanisms of activation10.1002/stem.150190 ↗
21. Shearing of synovial fluid activates latent TGF-β10.1016/j.joca.2012.07.006 ↗
22. Unloading results in rapid loss of TGFβ signaling in articular cartilage: role of loading-induced TGFβ signaling in maintenance of articular chondrocyte phenotype10.1016/j.joca.2016.05.018 ↗
23. Physiological and excessive mechanical compression of articular cartilage activates Smad2/3P signaling10.1016/j.joca.2014.04.024 ↗
24. Connective tissue growth factor contributes to joint homeostasis and osteoarthritis severity by controlling the matrix sequestration and activation of latent TGFβ10.1136/annrheumdis-2018-212964 ↗
25. Latent transforming growth factor-beta is produced by chondrocytes and activated by extracellular matrix vesicles upon exposure to 1,25-(OH)2D310.1016/S0021-9258(18)46938-4 ↗
26. Potential mechanisms for the plasmin-mediated release and activation of latent transforming growth factor-β1 from the extracellular matrix of growth plate chondrocytes110.1210/endo.140.12.7224 ↗
27. Activation of latent transforming growth factor β1 by stromelysin 1 in extracts of growth plate chondrocyte-derived matrix vesicles10.1359/jbmr.2001.16.7.1281 ↗
28. Transforming growth factor-beta: latent forms, binding proteins and receptors10.3109/08977199309029130 ↗
29. Heparin/heparan sulphate binding in the TGF-β cytokine superfamily10.1042/BST0340458 ↗
30. Label-free and direct visualization of multivalent binding of bone morphogenetic protein-2 with cartilage oligomeric matrix protein10.1021/acs.jpcb.8b08564 ↗
31. Comparison of the interactions of different growth factors and glycosaminoglycans
32. Endocytic regulation of TGF-β signaling10.1038/cr.2008.315 ↗
33. Computational and experimental characterizations of the spatiotemporal activity and functional role of TGF-β in the synovial joint10.1016/j.jbiomech.2023.111673 ↗
34. Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion10.1172/JCI113130 ↗
35. Oxygen gradients correlate with cell density and cell viability in engineered cardiac tissue10.1002/bit.20722 ↗
36. Nutrient gradients in engineered cartilage: metabolic kinetics measurement and mass transfer modelings10.1002/bit.21887 ↗
37. The influence of construct scale on the composition and functional properties of cartilaginous tissues engineered using bone marrow-derived mesenchymal stem cells10.1089/ten.tea.2011.0145 ↗
38. Effects of transforming growth factor-β on aggrecanase production and proteoglycan degradation by human chondrocytes in vitro10.1016/j.joca.2003.11.009 ↗
39. n-Layer BET adsorption isotherm modeling for multimeric Protein A ligand and its lifetime determination10.1016/j.jchromb.2020.122434 ↗
40. Heterogeneous engineered cartilage growth results from gradients of media-supplemented active TGF-β and is ameliorated by the alternative supplementation of latent TGF-β10.1016/j.biomaterials.2015.10.018 ↗
41. Characterization of the concentration-dependence of solute diffusivity and partitioning in a model dextran-agarose transport system10.1007/s12195-009-0076-4 ↗
42. Matrix production in large engineered cartilage constructs is enhanced by nutrient channels and excess media supply10.1089/ten.tec.2014.0451 ↗
43. Mechanical load modulates chondrogenesis of human mesenchymal stem cells through the TGF-β pathway10.1111/j.1582-4934.2009.00780.x ↗
44. Accumulation of exogenous activated TGF-β in the superficial zone of articular cartilage10.1016/j.bpj.2013.02.052 ↗
45. Direct visualization of the binding of transforming growth factor beta 1 with cartilage oligomeric matrix protein via high-resolution atomic force microscopy10.1021/acs.jpcb.0c07286 ↗
46. Changes in the expression of decorin and biglycan in human articular cartilage with age and regulation by TGF-β10.1016/0945-053X(94)90029-9 ↗
47. Expression of the heparan sulfate proteoglycan, perlecan, during mouse embryogenesis and perlecan chondrogenic activity in vitro10.1083/jcb.145.5.1103 ↗
48. Expression of decorin and biglycan by rabbit articular chondrocytes10.1016/S0167-4781(98)00044-X ↗
49. Autologous chondrocyte implantation (ACI) for aged patients: development of the proper cell expansion conditions for possible therapeutic applications10.1016/j.joca.2005.02.015 ↗
50. Distinct endocytic pathways regulate TGF-β receptor signalling and turnover10.1038/ncb975 ↗
51. TGFβ signaling in cartilage development and maintenance10.1002/bdrc.21058 ↗
52. A role for age-related changes in TGFβ signaling in aberrant chondrocyte differentiation and osteoarthritis10.1186/ar2896 ↗
53. Characterization of a membrane receptor for transforming growth factor-β in normal rat kidney fibroblasts10.1016/S0021-9258(18)90612-5 ↗
54. Transforming growth factor-β (TGF-β)-induced up-regulation of TGF-β receptors at the cell surface amplifies the TGF-β response10.1074/jbc.RA118.005763 ↗
55. Enhanced activity of transforming growth factor β1 (TGF-β1) bound to cartilage oligomeric matrix protein10.1074/jbc.M111.234716 ↗
56. Glucose- and TGF-ß-dependent matrix synthesis models explain heterogeneous matrix deposition in large engineered tissues
57. Glucose gradients influence zonal matrix deposition in 3D cartilage constructs10.1089/ten.tea.2014.0059 ↗
58. An injectable heparin-conjugated hyaluronan scaffold for local delivery of transforming growth factor β1 promotes successful chondrogenesis10.1016/j.actbio.2019.09.017 ↗
59. Molecular weight and concentration of heparin in hyaluronic acid-based matrices modulates growth factor retention kinetics and stem cell fate10.1016/j.jconrel.2015.04.034 ↗
60. Heparin-modified collagen gels for controlled release of pleiotrophin: potential for vascular applications10.3389/fbioe.2019.00074 ↗